Fractyl Health (GUTS) Stock Price, News & Analysis

Company Overview

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.

Key Stats

• Today's Range: $1.77 to $1.87
• 50-Day Range: $1.79 to $2.59
• 52-Week Range: $1.74 to $14.50
• Volume: 236,286 shs
• Average Volume: 319,297 shs
• Market Capitalization: $86.58 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $22.00
• Consensus Rating: Buy

Fractyl Health Stock Analysis - MarketRank™

Fractyl Health scored higher than 34% of companies evaluated by MarketBeat, and ranked 774th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Fractyl Health has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Fractyl Health has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Fractyl Health are expected to decrease in the coming year, from ($1.66) to ($2.55) per share.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.45% of the float of Fractyl Health has been sold short.

Short Interest Ratio / Days to Cover

Fractyl Health has a short interest ratio ("days to cover") of 7.8.

Change versus previous month

Short interest in Fractyl Health has recently increased by 16.29%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Fractyl Health does not currently pay a dividend.

Dividend Growth

Fractyl Health does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

12.45% of the float of Fractyl Health has been sold short.

Short Interest Ratio / Days to Cover

Fractyl Health has a short interest ratio ("days to cover") of 7.8.

Change versus previous month

Short interest in Fractyl Health has recently increased by 16.29%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: N/A

News Sentiment

Fractyl Health has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Fractyl Health this week, compared to 3 articles on an average week.

Search Interest

6 people have searched for GUTS on MarketBeat in the last 30 days.

MarketBeat Follows

Only 1 people have added Fractyl Health to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Fractyl Health insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $396,964.00 in company stock.

GUTS Stock Analysis - Frequently Asked Questions

How have GUTS shares performed this year?

Fractyl Health's stock was trading at $2.06 on January 1st, 2025. Since then, GUTS shares have decreased by 12.6% and is now trading at $1.80.
View the best growth stocks for 2025 here.

How were Fractyl Health's earnings last quarter?

Fractyl Health, Inc. (NASDAQ:GUTS) posted its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.02. The company had revenue of $0.01 million for the quarter.

When did Fractyl Health IPO?

Fractyl Health (GUTS) raised $110 million in an IPO on Friday, February 2nd 2024. The company issued 7,333,333 shares at a price of $15.00 per share.

How do I buy shares of Fractyl Health?

Shares of GUTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Fractyl Health own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Fractyl Health investors own include SoFi Technologies (SOFI), NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Alphabet (GOOG), JPMorgan Chase & Co. (JPM) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 1/21/2025
• Next Earnings (Estimated): 4/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:GUTS
• Previous Symbol: NASDAQ:GUTS
• CUSIP: N/A
• CIK: 1572616
• Web: fractyl.com
• Phone: 781-902-8800
• Fax: N/A
• Employees: 102
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $22.00
• High Stock Price Target: $26.00
• Low Stock Price Target: $18.00
• Potential Upside/Downside: +1,122.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($12.19)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-77,090,000.00
• Net Margins: -64,849.48%
• Pretax Margin: -64,849.48%
• Return on Equity: N/A
• Return on Assets: -57.21%

Debt

• Debt-to-Equity Ratio: 0.60
• Current Ratio: 5.58
• Quick Ratio: 5.57

Sales & Book Value

• Annual Sales: $120,000.00
• Price / Sales: 721.50
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 48,100,000
• Free Float: N/A
• Market Cap: $86.58 million
• Optionable: N/A
• Beta: N/A